Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space

03 Oct 2023

Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.

Radioisotope — Lilly moves into radioligand therapy for cancer with buyout of Point • Source: Shutterstock

Eli Lilly and Company continued a year of strategic bolt-on acquisitions on 3 October with the planned buyout of the radiopharmaceutical company POINT Biopharma Global Inc., with a tender offer that it expects to total approximately $1.4bn. The deal marks Lilly’s move into radioligand therapies for cancer, and Point’s early-stage pipeline and its isotope supply chain seems to have driven it, as it has already out-licensed a pair of late-stage radiopharmaceutical candidates that it is positioning to compete with Novartis AG’s Lutathera and Pluvicto.

In its statement on the deal, Lilly compared the transaction to previous moves to further its pipeline and capabilities in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.